JAMP-MOXIFLOXACIN TABLET

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Koupit nyní

Aktivní složka:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)

Dostupné s:

JAMP PHARMA CORPORATION

ATC kód:

J01MA14

INN (Mezinárodní Name):

MOXIFLOXACIN

Dávkování:

400MG

Léková forma:

TABLET

Složení:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG

Podání:

ORAL

Jednotky v balení:

30

Druh předpisu:

Prescription

Terapeutické oblasti:

QUINOLONES

Přehled produktů:

Active ingredient group (AIG) number: 0142242001; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2015-11-04

Charakteristika produktu

                                _JAMP-MOXIFLOXACIN_
_Page 1 of 71_
PRODUCT MONOGRAPH
PR
JAMP-MOXIFLOXACIN
Moxifloxacin Tablets
400 mg
(as moxifloxacin hydrochloride)
Antibacterial Agent
Manufactured by:
Date of Revision:
Jamp Pharma Corporation
September 18, 2020
1310 rue Nobel
Boucherville, Québec
J4B 5H3
Canada
SUBMISSION CONTROL NO: 239203
_JAMP-MOXIFLOXACIN_
_Page 2 of 71_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
........................................................................................................
5
WARNINGS AND PRECAUTIONS
......................................................................................
6
ADVERSE REACTIONS
..................................................................................................
14
DRUG INTERACTIONS
......................................................................................................
18
DOSAGE AND ADMINISTRATION
..................................................................................
20
OVERDOSAGE
.....................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 22
STORAGE AND STABILITY
..............................................................................................
29
SPECIAL HANDLING INSTRUCTIONS
...........................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 31
PART II: SCIENTIFIC INFORMATION
.................................................................................
32
PHARMACEUTICAL INFORMATION
....................................................................
                                
                                Přečtěte si celý dokument
                                
                            

Dokumenty v jiných jazycích

Charakteristika produktu Charakteristika produktu francouzština 18-09-2020

Vyhledávejte upozornění související s tímto produktem